AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2373139 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg suppository
Number of subjects: 12
Study 2373139 — intervention group
Group type: COMPARATOR
Intervention: 3 x 5 mg oral tablets
Number of subjects: 12
Study 7442081 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazoxide (median dose 400 mg/d)
Number of subjects: 11
Study 7442081 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral minoxidil (median dose 17.5 mg/d)
Number of subjects: 11
Study 31725467 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 1 (Scopus author affiliation data)
Number of subjects: 100
Study 31725467 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 2 (Corresponding author's description of disciplines)
Number of subjects: 100
Study 31725467 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 3 (Corresponding author's definition of disciplinarity)
Number of subjects: 100
Study 31725467 — intervention group
Group type: COMPARATOR
Intervention: Comparison of methods 1 and 3
Number of subjects: 100
Study 31725467 — intervention group
Group type: COMPARATOR
Intervention: Comparison of methods 2 and 3
Number of subjects: 100
Study 31725467 — intervention group
Group type: COMPARATOR
Intervention: Overall trend from 2005 to 2015
Number of subjects: 100
Study 30662058 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein Y-graft
Number of subjects: 60
Study 30662058 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 27996371 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined maneuver (injection of local anesthesia at the incision site, low‐pressure pneumoperitoneum, active gas suction, and pulmonary recruitment)
Number of subjects: 51
Study 27996371 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined maneuver
Number of subjects: 51
Study 27996371 — intervention group
Group type: COMPARATOR
Intervention: No maneuvers (control group B)
Number of subjects: 51
Study 26472419 — intervention group
Group type: EXPERIMENTAL
Intervention: B-mode ultrasound examination for double contour (DC) lesions
Number of subjects: 8
Study 26472419 — intervention group
Group type: EXPERIMENTAL
Intervention: B-mode ultrasound examination for tophus lesions
Number of subjects: 8
Study 26472419 — intervention group
Group type: EXPERIMENTAL
Intervention: B-mode ultrasound examination for aggregates
Number of subjects: 8
Study 26472419 — intervention group
Group type: EXPERIMENTAL
Intervention: B-mode ultrasound examination for erosions
Number of subjects: 8
Study 26472419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver reliability for tophus lesions
Number of subjects: 8
Study 26472419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver reliability for DC lesions
Number of subjects: 8
Study 26472419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver reliability for erosions
Number of subjects: 8
Study 26472419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver reliability for aggregates
Number of subjects: 8
Study 26472419 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver reliability for tophus lesions
Number of subjects: 8
Study 26472419 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver reliability for erosions
Number of subjects: 8
Study 26472419 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver reliability for aggregates
Number of subjects: 8
Study 26472419 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver reliability for DC lesions
Number of subjects: 8
Study 23713604 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g oral intradialytic protein (group 1)
Number of subjects: 14
Study 23713604 — intervention group
Group type: EXPERIMENTAL
Intervention: 29g oral intradialytic protein (group 2)
Number of subjects: 14
Study 23713604 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat snack supplementation (group 1)
Number of subjects: 14
Study 22033001 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone wax (Group 1)
Number of subjects: 66
Study 22033001 — intervention group
Group type: EXPERIMENTAL
Intervention: Spongostan (Group 2)
Number of subjects: 66
Study 22033001 — intervention group
Group type: EXPERIMENTAL
Intervention: Spongostan applied and removed after 10 minutes (Group 3)
Number of subjects: 66
Study 22033001 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 4) - no haemostatic agent applied
Number of subjects: 66
Study 18265981 — intervention group
Group type: EXPERIMENTAL
Intervention: New Technique (NT)
Number of subjects: 76
Study 18265981 — intervention group
Group type: COMPARATOR
Intervention: Conventional Technique (CT)
Number of subjects: 76
Study 17823678 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional syringe delivery system using a standardized 2-cartridge reloading and reinjection technique
Number of subjects: 35
Study 17823678 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-controlled delivery system using a technique whereby the second cartridge was reloaded without having to remove the needle from the injection site
Number of subjects: 35
Study 17823678 — intervention group
Group type: COMPARATOR
Intervention: Computer-controlled delivery system
Number of subjects: 35
Study 17823678 — intervention group
Group type: COMPARATOR
Intervention: Traditional syringe delivery system
Number of subjects: 35
Study 15867022 — intervention group
Group type: EXPERIMENTAL
Intervention: Momentary Sampling (MS)
Number of subjects: 10
Study 15867022 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaries
Number of subjects: 10
Study 15867022 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective Self-Report
Number of subjects: 10
Study 12225443 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Programme (CRP)
Number of subjects: 43
Study 12225443 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 43
Study 9444687 — intervention group
Group type: EXPERIMENTAL
Intervention: Level-of-care decision-support tool
Number of subjects: 1034
Study 7600855 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon and diazepam (active substances)
Number of subjects: 43
Study 7600855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 2213284 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics
Number of subjects: 0
Study 36118 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg prenalterol
Number of subjects: 6
Study 36118 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg prenalterol
Number of subjects: 6
Study 36118 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study 31125609 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid administration
Number of subjects: 299
Study 28229390 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g·kg‐1 body mass NaHCO3 (SBC2a and b)
Number of subjects: 15
Study 28229390 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g·kg‐1 body mass NaHCO3 (SBC3a and b)
Number of subjects: 15
Study 28229390 — intervention group
Group type: COMPARATOR
Intervention: Control treatments (CON1a and b)
Number of subjects: 15
Study 26124726 — intervention group
Group type: EXPERIMENTAL
Intervention: MCTd (Metacognitive training for delusions)
Number of subjects: 44
Study 26124726 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 44
Study 23587162 — intervention group
Group type: EXPERIMENTAL
Intervention: Peretinoin 300 mg daily
Number of subjects: 12
Study 23587162 — intervention group
Group type: EXPERIMENTAL
Intervention: Peretinoin 600 mg daily
Number of subjects: 12
Study 23587162 — intervention group
Group type: EXPERIMENTAL
Intervention: Peretinoin (both dosages)
Number of subjects: 12
Study 21768625 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented polyethylene acetabular component
Number of subjects: 55
Study 21768625 — intervention group
Group type: COMPARATOR
Intervention: Monobloc trabecular metal acetabular component
Number of subjects: 55
Study 19820031 — intervention group
Group type: EXPERIMENTAL
Intervention: GHR blockade (pegvisomant)
Number of subjects: 10
Study 19820031 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 17078309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (NIC) using a 21-mg transdermal patch
Number of subjects: 11
Study 17078309 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) treatment
Number of subjects: 11
Study 15020363 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral neck fractures
Number of subjects: 807
Study 15020363 — intervention group
Group type: COMPARATOR
Intervention: Control group without fractures
Number of subjects: 807
Study 15020363 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine fractures
Number of subjects: 807
Study 10762505 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP) treatment during the first night
Number of subjects: 10
Study 10762505 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP treatment
Number of subjects: 10
Study 10762505 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched without sleep-related breathing disorders)
Number of subjects: 10
Study 8960425 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (HBW 023) bolus of 0.07, 0.1, 0.2 or 0.4 mg.kg‐1 followed by infusion of 0.05, 0.06, 0.1 or 0.15 mg.kg‐1 over 48 h
Number of subjects: 40
Study 2060177 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ)
Number of subjects: 24
Study 2060177 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PDN)
Number of subjects: 24
Study 6303871 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ketoconazole daily
Number of subjects: 50
Study 6303871 — intervention group
Group type: COMPARATOR
Intervention: 500 mg griseofulvin daily
Number of subjects: 50
Study 30768449 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthotic intervention combined with scoliosis specific exercise (OE group)
Number of subjects: 0
Study 30768449 — intervention group
Group type: COMPARATOR
Intervention: Orthotic intervention only (OI group)
Number of subjects: 0
Study 27122063 — intervention group
Group type: EXPERIMENTAL
Intervention: Little cigar (Winchester)
Number of subjects: 21
Study 27122063 — intervention group
Group type: COMPARATOR
Intervention: Cigarette (own brand)
Number of subjects: 21
Study 27649689 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV)
Number of subjects: 329
Study 27649689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 25099645 — intervention group
Group type: EXPERIMENTAL
Intervention: NCE01
Number of subjects: 0
Study 25099645 — intervention group
Group type: EXPERIMENTAL
Intervention: NCE02
Number of subjects: 0
Study 25099645 — intervention group
Group type: EXPERIMENTAL
Intervention: NCE03
Number of subjects: 0
Study 22905660 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured workbook with self-monitoring exercises
Number of subjects: 51
Study 22905660 — intervention group
Group type: COMPARATOR
Intervention: Structured workbook without self-monitoring exercises
Number of subjects: 51
Study 20919542 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of a hypercalorie formula and a fiber‐containing formula with erythromycin stimulation within the first 3 days.
Number of subjects: 58
Study 20919542 — intervention group
Group type: COMPARATOR
Intervention: Isocalorie formula (control group).
Number of subjects: 58
Study 18416614 — intervention group
Group type: EXPERIMENTAL
Intervention: Rely-a-Bond
Number of subjects: 15
Study 18416614 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond
Number of subjects: 15
Study 18416614 — intervention group
Group type: EXPERIMENTAL
Intervention: M-Bond
Number of subjects: 15
Study 18416614 — intervention group
Group type: COMPARATOR
Intervention: All adhesive systems
Number of subjects: 15
Study 15811141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg)
Number of subjects: 86
Study 15811141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 12425502 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prescription for purulent rhinorrhea of less than 10 days' duration; 51 out of 149 pediatricians (34%) prescribed antibiotics.
Number of subjects: 149
Study 12425502 — intervention group
Group type: COMPARATOR
Intervention: Actual practice habits of pediatricians; review of office records.
Number of subjects: 149
Study 10479837 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced‐air active warming (group active, n = 25)
Number of subjects: 50
Study 10479837 — intervention group
Group type: COMPARATOR
Intervention: Passive thermal insulation with reflective blankets (group passive, n = 25)
Number of subjects: 50
Study 8630539 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 73
Study 8630539 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 73
Study 2210865 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG-anti-LPS therapy (more than 65 micrograms/ml)
Number of subjects: 18
Study 2210865 — intervention group
Group type: COMPARATOR
Intervention: Control group (less than 12.5 micrograms/ml)
Number of subjects: 18
Study 2210865 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG-anti-LPS therapy
Number of subjects: 18
Study 412207 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol = 50 mg t.d.s.
Number of subjects: 60
Study 412207 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl dopa = 250 mg t.d.s.
Number of subjects: 60
Study 412207 — intervention group
Group type: EXPERIMENTAL
Intervention: Propanolol = 40 mg t.d.s.
Number of subjects: 60
Study 412207 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine = 0.2 mg t.d.s.
Number of subjects: 60
Study 412207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 412207 — intervention group
Group type: COMPARATOR
Intervention: Control = no tablets
Number of subjects: 60
Study 30844114 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based self-learning (n = 8)
Number of subjects: 16
Study 30844114 — intervention group
Group type: COMPARATOR
Intervention: Didactic training (n = 8)
Number of subjects: 16
Study 28092069 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimuscarinics and beta‐3 adrenergic agonists (alone or in combination with standard BPE/BPO therapy)
Number of subjects: 0
Study 28092069 — intervention group
Group type: COMPARATOR
Intervention: Standard alpha‐adrenergic blockade and 5‐alpha reductase inhibitor therapy
Number of subjects: 0
Study 25358450 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesamorelin 1 mg administered daily for 14 days
Number of subjects: 38
Study 25358450 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesamorelin 2 mg administered daily for 14 days
Number of subjects: 38
Study 25358450 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesamorelin (1 or 2 mg) administered daily for 14 days
Number of subjects: 38
Study 23303891 — intervention group
Group type: COMPARATOR
Intervention: Patient information leaflet control group
Number of subjects: 3562
Study 23303891 — intervention group
Group type: EXPERIMENTAL
Intervention: Five minutes of structured brief advice
Number of subjects: 3562
Study 23303891 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 minutes of brief lifestyle counselling
Number of subjects: 3562
Study 21263369 — intervention group
Group type: EXPERIMENTAL
Intervention: Trusting relationship with medical staff
Number of subjects: 204
Study 21263369 — intervention group
Group type: COMPARATOR
Intervention: Length of stay in the intensive care unit
Number of subjects: 204
Study 21263369 — intervention group
Group type: COMPARATOR
Intervention: Family's emotional reactions
Number of subjects: 204
Study 19501215 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine 200 mg bid coadministered with ethinylestradiol/norethindrone
Number of subjects: 30
Study 23051684 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine patch monotherapy
Number of subjects: 206
Study 23051684 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine plus rivastigmine patch
Number of subjects: 206
Study 16430026 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram-ratiopharm film-coated tablets (test preparation)
Number of subjects: 20
Study 16430026 — intervention group
Group type: COMPARATOR
Intervention: Tablets of a reference preparation (control)
Number of subjects: 20
Study 12856477 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (INFB-1b) therapy
Number of subjects: 15
Study 12856477 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (Control group)
Number of subjects: 15
Study 9856290 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Assisted Cognitive-Behaviour Therapy (MACT)
Number of subjects: 0
Study 9856290 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study 7620474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg three times daily
Number of subjects: 29
Study 7620474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 2711919 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily for 2 weeks
Number of subjects: 10
Study 889650 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 4 mg/kg
Number of subjects: 157
Study 889650 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin 0.055 ml/kg
Number of subjects: 157
Study 889650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg/kg
Number of subjects: 157
Study 889650 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 0.7 mg/kg after intubation
Number of subjects: 157
Study 889650 — intervention group
Group type: COMPARATOR
Intervention: Saline after intubation
Number of subjects: 157
Study 12001556 — intervention group
Group type: EXPERIMENTAL
Intervention: Activator MAA
Number of subjects: 26
Study 12001556 — intervention group
Group type: COMPARATOR
Intervention: Silencor MAA
Number of subjects: 26
Study 12001556 — intervention group
Group type: EXPERIMENTAL
Intervention: Both appliances
Number of subjects: 26
Study 29754836 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 μg oral, four times daily for 8 weeks
Number of subjects: 104
Study 29754836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 29754836 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 104
Study 27335011 — intervention group
Group type: COMPARATOR
Intervention: Tracer group (1 ml carbon nanoparticle suspension)
Number of subjects: 90
Study 27335011 — intervention group
Group type: COMPARATOR
Intervention: Drug-load group (3 ml carbon nanoparticle-epirubicin suspension)
Number of subjects: 90
Study 27335011 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (no lymphatic tracers)
Number of subjects: 90
Study 24744384 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (ExT) in MetS subjects
Number of subjects: 22
Study 24744384 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (ExT) in healthy control subjects
Number of subjects: 22
Study 24744384 — intervention group
Group type: COMPARATOR
Intervention: Control group (inactive) in MetS subjects
Number of subjects: 22
Study 24744384 — intervention group
Group type: COMPARATOR
Intervention: Control group (inactive) in healthy control subjects
Number of subjects: 22
Study 23302708 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic VR environment (Group D)
Number of subjects: 16
Study 23302708 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic and static VR training (Group D1)
Number of subjects: 16
Study 23302708 — intervention group
Group type: COMPARATOR
Intervention: Static VR environment (Group S)
Number of subjects: 16
Study 20938962 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed adenotonsillectomy (electrocautery tonsillectomy with curettage adenoidectomy)
Number of subjects: 72
Study 20938962 — intervention group
Group type: COMPARATOR
Intervention: Cold adenotonsillectomy
Number of subjects: 72
Study 18825579 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis Self-Management Programme (ASMP) with added exercise component
Number of subjects: 95
Study 18825579 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study 16321199 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional open craniotomy (COC)
Number of subjects: 2464
Study 16321199 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed‐tomography guided aspiration (CTGA)
Number of subjects: 2464
Study 16321199 — intervention group
Group type: EXPERIMENTAL
Intervention: Key‐hole approach (KHA)
Number of subjects: 2464
Study 12000204 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 245
Study 12000204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 10441920 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-session prevention program teaching social resistance skills
Number of subjects: 2209
Study 10441920 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2209
Study 7874093 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PCS
Number of subjects: 33
Study 7874093 — intervention group
Group type: COMPARATOR
Intervention: Patients with MHI without PCS
Number of subjects: 33
Study 7874093 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 33
Study 2116532 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry (IC)
Number of subjects: 49
Study 2116532 — intervention group
Group type: COMPARATOR
Intervention: Curreri formula (CURR)
Number of subjects: 49
Study 2116532 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 2116532 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower calorie:nitrogen ratio
Number of subjects: 49
Study 708150 — intervention group
Group type: EXPERIMENTAL
Intervention: GOBA 1.0 g
Number of subjects: 24
Study 708150 — intervention group
Group type: EXPERIMENTAL
Intervention: GOBA 2.0 g
Number of subjects: 24
Study 708150 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg (D)
Number of subjects: 24
Study 708150 — intervention group
Group type: COMPARATOR
Intervention: Alcohol 0.5 g/kg
Number of subjects: 24
Study 708150 — intervention group
Group type: EXPERIMENTAL
Intervention: GOBA 1.0 g + Alcohol 0.5 g/kg
Number of subjects: 24
Study 708150 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 24
Study 30784635 — intervention group
Group type: EXPERIMENTAL
Intervention: CRADLE Vital Sign Alert intervention
Number of subjects: 536223